Use of s1p receptor modulator

Abstract

Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression.

1 . A method for preventing, inhibiting or treating a condition effected by BDNF production, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb as defined hereinabove. 
     
     
         2 . The method of  claim 1 , where the condition affected by BDNF production is selected from one or more of diabetes, nervous system injured by wound, congenital conditions, neurodegenerative diseases, sensory nerve dysfunction, obesity, cognitive impairment, attention deficit disorders, sleep disorders or depressive disorders. 
     
     
         3 . A method for inducing the production of BDNF, in a subject, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb. 
     
     
         4 . A method for making a patient feel better, e.g. by removing symptoms of depression, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb. 
     
     
         5 . A method according to  claim 1 , wherein the S1P receptor modulator is administered intermittently. 
     
     
         6 . A pharmaceutical composition for use in a method according to  claim 1 , comprising an S1P receptor modulator, e.g. a compound of formulae I to XIb as defined hereinabove, together with one or more pharmaceutically acceptable diluents or carriers therefor. 
     
     
         7 . A method according to  claim 1  comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective non-toxic amount of a S1P receptor modulator and a second therapeutic substance. 
     
     
         8 . A pharmaceutical combination, e.g. a kit, comprising a) a first agent which is a S1P receptor modulator e.g. a compound of formulae I to XIb as defined herein above, in free form or in pharmaceutically acceptable salt form, and b) instructions for use in a BDNF-related condition or disease, as described herein. 
     
     
         9 . The combination of  claim 7 , wherein the BDNF-related condition or disease selected from one or more of diabetes, nervous system injured by wound, congenital conditions, neurodegenerative diseases, sensory nerve dysfunction, obesity, cognitive impairment, attention deficit disorders, sleep disorders or depressive disorders. 
     
     
         10 . A method according to  claim 1 , wherein the S1P receptor modulator is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form.